Barry Ticho explains the novel drug that the company is developing to tackle Dravet Syndrome as well as how the company’s stock price decline isn’t reflective of the true value of the therapy the company is hoping to commercialize.
Barry Ticho explains the novel drug that the company is developing to tackle Dravet Syndrome as well as how the company’s stock price decline isn’t reflective of the true value of the therapy the company is hoping to commercialize.
Copyright © 2024 | WordPress Theme by MH Themes
